Introduction
============

Gastric cancer (GC) is one of the most common malignant tumors of the digestive system and has had a significant impact on public health. GC is the 4^th^ most common malignant tumor and the 3^rd^ leading cause of cancer-related mortality [@B1]. Lymph node metastasis (LNM) has an important effect on the prognosis and the extent of lymph node dissection of GC [@B2]-[@B4]. However, whether age has an impact on LNM has not yet been conclusively determined. Nelen et al. analyzed the clinicopathological characteristics of patients with GC who were under and over 70 years of age and concluded that age was closely related to LNM [@B5]. However, a study by Liu et al. involving 198 patients with GC who were under 40 years of age and 1,096 patients with GC who were over 55 years of age found that there was no significant difference in N stage between different age groups [@B6]. In patients with early gastric cancer (EGC) who may receive limited lymph node dissection (D1 or D1+ lymph node dissection), there are no reports about whether LNM rates differ between different age groups. Therefore, the current study incorporated large sample data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate the effect of age on LNM in patients with GC.

Patients and Methods
====================

Patients
--------

A total of 22,808 patients with GC who underwent gastrectomy between January 1988 and December 2013 in the SEER database (Nov 2015) were eligible for this study. The inclusion criteria were as follows: (1) histological determined GC (ICD-0-3M-8140/3, M-8142/3 through M-8145/3, M-8210/3, M-8211/3, M-8255/3, M-8260/3 through M-8263/3, M-8310/3, M-8323/3, M-8480/3, M-8481/3, and M-8490/3); (2) no record of previous malignant tumors before being diagnosed with GC; (3) number of examined nodes (ELNs) \> 1; and (4) with complete clinicopathological information. The following patients were excluded from the study: (1) patients with distant metastasis (M1); (2) patients who received preoperative radiotherapy; and (3) patients with cardia carcinoma. Fig. [1](#F1){ref-type="fig"} shows the stepwise process through which patients were selected for the study. The informed consent and institutional review board approval are not required in the study because the SEER database is open access without identification for all patients.

Variables and Definitions
-------------------------

The following variables were included in the study: age, race, gender, depth of invasion, surgery type, tumor size, histological type, number of ELNs and the number of positive lymph nodes. Age was divided into 20-39 (defined as young), 40-49, 50-59, 60-69, 70-79 and ≥ 80 groups. Race included white, black and other. Postoperative pathological stage was defined according to the seventh edition of the AJCC/UICC stage standard. Surgery type analyzed in the study included partial gastrectomy (distal or proximal gastrectomy), near total/total gastrectomy, gastrectomy not otherwise specified (NOS) and combined resection according to SEER\'s surgical information. Cases were divided into groups of ≤ 45 mm and \> 45 mm according to the median tumor size. The histological types in this study were classified into intestinal type (papillary adenocarcinoma and tubular adenocarcinoma) and diffuse type (carcinoma diffuse type, signet ring cell carcinoma and linitis plastica) according to the Lauren classification. We use "International Classification of Diseases for Oncology, 3rd Edition" to identify the histological type in SEER database [@B7]. And the number of ELNs was divided into groups of ≤ 15 and \> 15 according to National Comprehensive Cancer Network (NCCN) standards [@B8].

Statistical Analysis
--------------------

Chi-square tests were used to analyze the relationships between age and LMN rates in each T stage. The Jonckheere-Terpstra test was used to analyze the relationship between age and the number of positive lymph nodes in patients with LNM. Binary logistic regression analysis was used to analyze the risk factors for LNM and the covariates included age, gender, race, surgery type, tumor size, histological type and the number of ELNs. Linear regression was used to analyze the relationships between LNM rates and age. Statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). All statistical tests were 2-sided, and a P value \< 0.05 was considered statistically significant.

Results
=======

Patient Demographics and Tumor Characteristics
----------------------------------------------

A total of 22,808 patients were enrolled in this study. Overall, 761 (3.3%) patients were under 40 years of age, 1,868 (8.2%) patients were between 40 and 49 years of age, 3,375 (14.8%) patients were between 50 and 59 years of age, 5,429 (23.8%) patients were between 60 and 69 years of age, 6,990 (30.6%) patients were between 70 and 79 years of age, and 4,385 (19.2%) patients were older than 80 years of age. A total of 4,849 (21.3%) patients had T1 disease, 2,735 (12%) patients had T2 disease, 8,267 (36.2%) patients had T3 disease, and 6,957 (30.5%) patients had T4 disease. A total of 9,028 (39.6%) patients had N0 stage, 4,163 (18.3%) patients had N1 stage, 4,254 (18.7%) patients had N2 stage, and 5,360 (23.5%) patients had N3 stage. Patients in different age groups differed significantly with respect to race, gender, T stage, N stage, surgery type, tumor size and histological type (Table [1](#T1){ref-type="table"}).

Lymph Node Dissection in Each Age Group
---------------------------------------

Overall, the median number of ELNs was 12 (interquartile range \[IQR\], 7-20). The median numbers of ELNs were 14 (IQR, 9-23), 15 (IQR, 8-23), 15 (IQR, 7-21), 13 (IQR, 7-21), 12 (IQR, 6-19) and 10 (IQR, 5-16.5) for patients in the 20-39, 40-49, 50-59, 60-69, 70-79 and ≥ 80 age groups, respectively (P \< 0.001).

The median numbers of ELNs were 10 (IQR, 5-18), 12 (IQR, 6-19), 13 (IQR, 7-21) and 13 (IQR, 7-21) in patients with T1, T2, T3 and T4 disease, respectively. The median numbers of ELNs differed significantly between patients with different age groups whose diseases were of the same T stage (all P \< 0.001) (Table [2](#T2){ref-type="table"}).

Association between Age and LNM
-------------------------------

A total of 13,780 (60.4%) patients presented with LNM. The LNM rates were 69.6%, 66.1%, 64.7%, 61.8%, 57.8% and 55.6% for patients in the 20-39, 40-49, 50-59, 60-69, 70-79 and ≥ 80 age groups, respectively (P \< 0.001). When stratified by depth of invasion, the LNM rates and the median number of positive lymph nodes were correlated with age in patients whose diseases were of the same T stage (all P \< 0.01) (Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}).

Univariate and Multivariate Analysis of LNM
-------------------------------------------

Univariate analysis showed that age was associated with LNM in the entire group and in each T stage (Table [S1](#SM0){ref-type="supplementary-material"} to Table [S5](#SM0){ref-type="supplementary-material"}). Multivariate analysis showed that age, race, surgical type, tumor size, histological type, T stage and number of ELNs were independent predictors of LNM in the entire group (Table [S1](#SM0){ref-type="supplementary-material"}). Age was also an independent predictor for LNM in patients with T1 disease (P = 0.031), but was not an independent predictor for LNM in patients with T2-T4 disease (Table [5](#T5){ref-type="table"}, Table [S2](#SM0){ref-type="supplementary-material"} to Table [S5](#SM0){ref-type="supplementary-material"}).

Linear Regression Analysis of Age and LNM Rates in Patients with EGC
--------------------------------------------------------------------

The LNM rate was 19.6% among the 4,849 patients with EGC. A total of 3,360 (69.3%) patients had ≤ 15 ELNs, and 1,489 (30.7%) patients had \> 15 ELNs. The LNM rates were 17.1% and 25.3% in the \> 15 and the ≤ 15 ELNs groups, respectively. Linear regression analysis showed that young patients with EGC are at higher risk for LNM than other age patients (all patients with T1 disease, P = 0.003; ELNs ≤ 15, P = 0.030 and ELNs \> 15, P = 0.046) (Fig. [2](#F2){ref-type="fig"}).

Discussion
==========

Worldwide, GC is still one of the major malignant tumors that affect human health. LNM is the most common pattern of metastasis in GC and is an important factor for determining the treatment options and predicting its prognosis. Previous study showed that the LNM rates of EGC range from 8.4% to 20.1% [@B9], while the LNM rate of advanced GC is as high as 70% [@B10]. Bruno et al. reported that the biological characteristics of node-negative GC are mild with good prognosis. In contrast, node-positive GC has a poor prognosis [@B3]. Wu et al. analyzed the prognostic data of 510 patients with GC and found that the 5-year survival rates for patients without LNM and with 1-4 positive lymph nodes were 89.5% and 62.8%, respectively, with significant difference [@B4].

Many scholars have systematically investigated the risk factors for LNM in GC. These studies found that the depth of invasion, histological type, tumor size, macroscopic type and lymphovascular invasion were closely related to LNM [@B11]-[@B14]. However, whether age affects LNM is still controversial. Pisanu et al. found no significant difference in N stage between patients with GC who were over and under 50 years of age [@B15]. However, Smith et al. compared the clinicopathological data of 30 patients under 35 years of age with that of 320 patients over 35 years of age and found that the LNM rates of the two age groups were significantly different [@B16]. However, these studies incorporated small sample data and analyzed age only as a binary categorical variable; thus, these results need to be validated in future studies. In the current study, a large number of cases with number of ELNs ≥ 1 were retrospectively analyzed, and age was divided into continuous intervals so that its relationship with LNM could be elucidated. For the entire group, univariate analysis found that age was closely related to LNM, and multivariate analysis showed that age was an independent predictor of LNM (P \< 0.001, Table [S1](#SM0){ref-type="supplementary-material"}). Additionally, in the current study, we stratified analyzed the impact of age on LNM by different T stage. The results indicated that age is associated with LNM in patients with GC. We also recalculated patients with a number of ELNs \> 15 for analysis. Univariate analysis showed that age, race, surgery type, tumor size, histological type, and T stage were associated with LNM. Multivariate analysis founded that tumor size, histological type, and T stage were independent predictors of LNM. Although the effect of age on LNM was not statistically significant (P = 0.063), it was observed that the odds ratios of other age groups were all less than 1 compared to young patients (Table [S6](#SM0){ref-type="supplementary-material"}), which indicating a higher risk of LNM in young patients. Gurzu et al. found that VEGF, a gene increases the likelihood of tumor invasion and LMN in GC, is overexpressed in younger patients with GC [@B17]. Bao et al. argued that MDM4, which is related to LNM and a poor prognosis in GC, is overexpressed in younger patients compared with older patients [@B18]. Based on the abovementioned studies and the results of our study, we hypothesized that age is closely associated with LNM in GC.

Some studies have shown that patients with EGC who underwent limited lymph node dissection can obtain a similar long-term survival compared with patients who underwent D2 radical surgery and the quality of life after surgery is significantly improved [@B19]-[@B23]. According to \"Japanese Gastric Cancer Treatment Guidelines\", limited lymph node dissection is feasible for clinical node-negative EGC [@B24]. But for EGC patients with LNM, limited lymph node dissection carries a high risk of postoperative recurrence [@B25], [@B26]. However, there is no accurate way to identify LNM in EGC. Preoperative CT and endoscopic ultrasonography can only diagnose LMN with accuracies of 50% and 70%, respectively [@B27]. Therefore, identifying the risk factors for LNM in EGC is important. Similar to previous studies, our study found that tumor size and histological type were independent predictive factors for LNM in patients with EGC [@B28], [@B29]. However, multivariate analysis showed that age is an independent predictor for LNM in EGC (compared with young patients, the odds ratios for LNM in the other age groups ranged from 0.59 to 0.77). A linear regression analysis showed that the LNM rate was higher in young patients with EGC than in other age patients. EGC is a special type of GC which is located only in the mucosa and submucosa. Because lymphatic or blood vessels are less in the mucosa and submucosa, the risk factors of LNM in EGC are quite different from advanced GC. In this study, we found that age was an independent predictor for LNM in patients with T1 disease, but was not an independent predictor for LNM in patients with T2-T4 disease. The higher LNM rate in young patients with EGC compared to other age patients may be related to higher malignant potential of tumor in young patients. In the study conducted by Park et al., age was closely related to the tumor malignancy, and GC in younger patients was more aggressive than older patients [@B30]. Based on previous study and findings of our study, we conclude that age has an important effect on LNM and the treatment options for EGC.

To our knowledge, this study for the first time investigates the relationship between age and LNM in patients with GC. We found that age is an independent predictor for LNM in patients with EGC and that LNM is more common in young patients with EGC than in other age patients. Therefore, clinicians should pay more attention to the preoperative assessment of lymph node status in young patients with EGC and realize that limited lymph node dissection may not be appropriate for these patients.

Our study had limitations that must be considered. First, this study had a retrospective design, which may have led to bias in the data selection process. Second, the information of neoadjuvant chemotherapy is not available in the SEER database, which may have a certain impact on LNM. Third, since the SEER database is a multi-center database, the quality of surgery may vary widely between centers. Nevertheless, we determined the impact of age on LNM in patients with EGC. These findings may serve as a basis for prospective studies and may ultimately affect the clinical treatment strategies for young patients with EGC.
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LNM

:   lymph node metastasis

GC

:   gastric cancer

ELNs

:   examined lymph nodes

IQR

:   interquartile range

EGC

:   early gastric cancer

SEER

:   the Surveillance, Epidemiology, and End Results

NOS

:   not otherwise specified

NCCN

:   National Comprehensive Cancer Network

CI

:   confidence interval
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![Linear Regression Analysis of the Relationship between Age and LNM Rates in Patients with EGC. LNM rate show a decrease trend with age increasing in (A) All patients with T1 disease (R^2^ Linear = 0.914, P = 0.003), (B) T1 patients with number of ELNs ≤ 15 (R^2^ Linear = 0.730, P = 0.030) and (C) T1 patients with \> 15 ELNs (R^2^ Linear = 0.641, P = 0.046)](jcav10p4389g002){#F2}

###### 

Clinicopathological characteristics of each age group

                                 Age at diagnosis   P\*                                                        
  ------------------------------ ------------------ -------- ------ ------ ------ ------ ---------- ---------- ----------
  Age at diagnosis                                                                                             
  20-39                          761                (3.3)                                                      
  40-49                          1868               (8.2)                                                      
  50-59                          3375               (14.8)                                                     
  60-69                          5429               (23.8)                                                     
  70-79                          6990               (30.6)                                                     
  80+                            4385               (19.2)                                                     
  Race                                                                                                         \< 0.001
  White                          13337              (58.5)   56.0   51.9   52.9   56.2   60.1       66.2       
  Black                          3433               (15.1)   17.9   21.4   19.2   16.0   13.0       10.7       
  Other                          6038               (26.5)   26.1   26.7   27.9   27.8   26.8       23.1       
  Gender                                                                                                       \< 0.001
  Male                           12853              (56.4)   48.4   55.5   61.3   61.5   56.9       47.1       
  Female                         9955               (43.6)   51.6   44.5   38.7   38.5   43.1       52.9       
  T stage                                                                                           \< 0.001   
  T1                             4849               (21.3)   14.8   18.2   19.9   21.8   22.9       21.4       
  T2                             2735               (12.0)   10.1   10.5   11.4   11.7   12.1       13.7       
  T3                             8267               (36.2)   35.0   37.5   35.6   36.6   35.8       36.7       
  T4                             6957               (30.5)   40.1   33.8   33.2   29.9   29.2       28.3       
  N stage                                                                                           \< 0.001   
  N0                             9028               (39.6)   30.4   33.9   35.3   38.2   42.2       44.4       
  N1                             4163               (18.3)   15.6   17.7   16.7   18.0   18.5       20.0       
  N2                             4254               (18.7)   23.3   18.8   19.3   18.9   18.1       17.9       
  N3                             5363               (23.5)   30.7   29.6   28.6   24.9   21.2       17.7       
  Surgery type                                                                                      \< 0.001   
  Partial gastrectomy            15556              (68.2)   58.2   60.0   62.4   64.9   70.4       78.5       
  Near total/total gastrectomy   4053               (17.8)   22.5   22.7   21.2   20.1   16.2       11.8       
  Gastrectomy NOS                297                (1.3)    1.6    1.6    1.8    1.2    1.3        0.9        
  Combined resection             2902               (12.7)   17.7   15.7   14.6   13.8   12.1       8.8        
  Tumor size                                                                                        \< 0.001   
  ≤ 45mm                         10092              (44.2)   40.5   41.8   42.4   45.0   44.9       45.3       
  \> 45mm                        9792               (42.9)   44.8   43.5   42.8   41.9   42.6       44.2       
  Unknown                        2924               (12.8)   14.7   14.7   14.8   13.1   12.5       10.4       
  Histological type                                                                      \< 0.001              
  Intestinal                     21038              (92.2)   85.7   87.9   90.0   91.7   93.8       95.2       
  Diffuse                        1770               (7.8)    14.3   12.1   10.0   8.3    6.2        4.8        

\*P value from chi-square test

Due to rounding, the values in parentheses may not add up to 100

**Abbreviations:** NOS, not otherwise specified

###### 

Number of ELNs in each age group by T stage

  Age           N       Median   25^th^, 75^th^   P\*    
  ------------- ------- -------- ---------------- ------ ----------
  All T stage                                            \< 0.001
  Total         22808   12       7                20     
  20-39         761     14       9                23     
  40-49         1868    15       8                23     
  50-59         3375    15       8                23     
  60-69         5429    13       7                21     
  70-79         6990    12       6                19     
  80+           4385    10       5                16.5   
  T stage T1                                             \< 0.001
  Total         4849    10       5                18     
  20-39         113     12       6                19.5   
  40-49         340     13       6                22     
  50-59         671     12       6                20     
  60-69         1185    11       6                19     
  70-79         1603    9        5                16     
  80+           937     8        4                14     
  T stage T2                                             \< 0.001
  Total         2735    12       6                19     
  20-39         77      15       9                22     
  40-49         196     13.5     7.25             22     
  50-59         385     14       8                23     
  60-69         635     13       7                20     
  70-79         843     11       7                18     
  80+           599     9        5                15     
  T stage T3                                             \< 0.001
  Total         8267    13       7                21     
  20-39         266     14       9                21.3   
  40-49         701     15       9                22     
  50-59         1200    15       9                24     
  60-69         1988    14       8                22     
  70-79         2503    12       7                20     
  80+           1609    10       6                17     
  T stage T4                                             \< 0.001
  Total         6957    13       7                21     
  20-39         305     15       8                24.5   
  40-49         631     15       9                23     
  50-59         1119    15       9                23     
  60-69         1621    14       8                22     
  70-79         2041    12       7                20     
  80+           1240    11       6                18     

\*P value from Jonckheere-Terpstra test

###### 

LNM rates in each age group by T stage

  Age           N       LN positive   P\*    
  ------------- ------- ------------- ------ ----------
  All T stage                                \< 0.001
  Total         22808   13780         60.4   
  20-39         761     530           69.6   
  40-49         1868    1235          66.1   
  50-59         3375    2182          64.7   
  60-69         5429    3356          61.8   
  70-79         6990    4040          57.8   
  80+           4385    2437          55.6   
  T stage T1                                 0.001
  Total         4849    949           19.6   
  20-39         113     30            26.5   
  40-49         340     77            22.6   
  50-59         671     144           21.5   
  60-69         1185    248           20.9   
  70-79         1603    283           17.7   
  80+           937     167           17.8   
  T stage T2                                 0.001
  Total         2735    1237          45.2   
  20-39         77      42            54.5   
  40-49         196     98            50     
  50-59         385     198           51.4   
  60-69         635     281           44.3   
  70-79         843     361           42.8   
  80+           599     257           42.9   
  T stage T3                                 \< 0.001
  Total         8267    5913          71.5   
  20-39         266     200           75.2   
  40-49         701     526           75     
  50-59         1200    913           76.1   
  60-69         1988    1481          74.5   
  70-79         2503    1749          69.9   
  80+           1609    1044          64.9   
  T stage T4                                 \< 0.001
  Total         6957    5681          81.7   
  20-39         305     258           84.6   
  40-49         631     534           84.6   
  50-59         1119    927           82.8   
  60-69         1621    1346          83     
  70-79         2041    1647          80.7   
  80+           1240    969           78.1   

\*P value from chi-square test

###### 

Uni- and multivariate binary logistic regression analysis of the relationship between age and LNM in each T stage

  Age           Univariate Analysis          Multivariate Analysis                                     
  ------------- --------------------- ------ ----------------------- --------- -- ------ ------ ------ ---------
  All T stage                                                        \<0.001                           \<0.001
  20-39         Ref                                                               Ref                  
  40-49         0.85                  0.71   1.02                    0.081        0.92   0.75   1.13   0.435
  50-59         0.80                  0.67   0.95                    0.009        0.91   0.75   1.11   0.349
  60-69         0.71                  0.60   0.83                    \<0.001      0.87   0.72   1.05   0.146
  70-79         0.60                  0.51   0.70                    \<0.001      0.76   0.63   0.91   0.003
  80+           0.55                  0.46   0.64                    \<0.001      0.70   0.58   0.85   \<0.001
  T stage T1                                                         0.016                             0.031
  20-39         Ref                                                               Ref                  
  40-49         0.81                  0.50   1.32                    0.398        0.74   0.45   1.23   0.247
  50-59         0.76                  0.48   1.19                    0.230        0.77   0.48   1.22   0.259
  60-69         0.73                  0.47   1.14                    0.165        0.72   0.46   1.13   0.153
  70-79         0.59                  0.38   0.92                    0.019        0.59   0.38   0.93   0.022
  80+           0.60                  0.38   0.94                    0.026        0.59   0.37   0.93   0.023
  T stage T2                                                         0.016                             0.100
  20-39         Ref                                                               Ref                  
  40-49         0.83                  0.49   1.41                    0.499        0.83   0.49   1.41   0.488
  50-59         0.88                  0.54   1.44                    0.617        0.85   0.52   1.40   0.524
  60-69         0.66                  0.41   1.06                    0.088        0.66   0.41   1.07   0.093
  70-79         0.62                  0.39   1.00                    0.049        0.65   0.40   1.04   0.073
  80+           0.63                  0.39   1.01                    0.054        0.67   0.41   1.08   0.098
  T stage T3                                                         0.023                             0.138
  20-39         Ref                                                               Ref                  
  40-49         0.99                  0.72   1.38                    0.961        1.00   0.72   1.40   0.984
  50-59         1.05                  0.77   1.43                    0.757        1.04   0.76   1.42   0.798
  60-69         0.96                  0.72   1.30                    0.808        1.01   0.75   1.36   0.960
  70-79         0.77                  0.57   1.02                    0.072        0.83   0.62   1.12   0.217
  80+           0.61                  0.45   0.82                    0.001        0.71   0.52   0.96   0.025
  T stage T4                                                         0.001                             0.376
  20-39         Ref                                                               Ref                  
  40-49         1.00                  0.69   1.47                    0.988        1.00   0.68   1.47   0.991
  50-59         0.88                  0.62   1.25                    0.469        0.89   0.63   1.27   0.523
  60-69         0.89                  0.64   1.25                    0.505        0.94   0.67   1.32   0.710
  70-79         0.76                  0.55   1.06                    0.105        0.85   0.61   1.19   0.353
  80+           0.65                  0.46   0.91                    0.013        0.79   0.56   1.12   0.184

**Abbreviations:** NOS, not otherwise specified; Ref, reference; CI, confidence interval. Covariates included age, gender, race, surgery type, tumor size, histological type, and the number of ELNs.

###### 

Association between age and the number of positive LNs in patients with LNM

  -------------------------------------------------------------
  Age           Median\        25^th^, 75^th^        
                Positive LNs                         
  ------------- -------------- ---------------- ---- ----------
  All T stage                                        \< 0.001

  Total         5              2                10   

  20-39         6              3                11   

  40-49         6              2                11   

  50-59         6              2                10   

  60-69         5              2                10   

  70-79         4              2                9    

  80+           4              2                8    

  T stage T1                                         0.002

  Total         2              1                4    

  20-39         2.5            1                6    

  40-49         2              1                6    

  50-59         2              1                4    

  60-69         2              1                4    

  70-79         2              1                4    

  80+           1              1                3    

  T stage T2                                         \< 0.001

  Total         3              1                5    

  20-39         4              2                6    

  40-49         3              1                5    

  50-59         3              1                7    

  60-69         3              1                5    

  70-79         2              1                5    

  80+           2              1                4    

  T stage T3                                         \< 0.001

  Total         5              2                9    

  20-39         6              3                11   

  40-49         6              2                10   

  50-59         6              3                10   

  60-69         5              2                10   

  70-79         4              2                9    

  80+           4              2                8    

  T stage T4                                         \< 0.001

  Total         6              3                12   

  20-39         6              3                13   

  40-49         7              3                12   

  50-59         7              3                12   

  60-69         6              3                12   

  70-79         6              3                12   

  80+           5              2                11   
  -------------------------------------------------------------

\*P value from Jonckheere-Terpstra test
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